New research: Salipro® enables the discovery of a new drug target for psychiatric disorders
New Research Highlight!
We are excited to share that our Salipro® technology has been instrumental in a groundbreaking study published in the EMBO Journal by Misha Kudryashev’s lab at the Max Delbrück Center. The researchers have identified a new potential drug target for psychiatric and gastrointestinal disorders.
By stabilizing the elusive serotonin-gated 5-HT3A receptor, our Salipro® technology enabled the scientists to uncover a critical intermediate structure that could lead to novel therapeutic approaches. This breakthrough highlights the potential of our platform in unlocking challenging drug targets and accelerating the development of innovative medicines.
Why is the 5-HT3A receptor important?
The serotonin-gated 5-HT3A receptor plays a vital role in neurotransmission and is implicated in various conditions, including anxiety, depression, and irritable bowel syndrome. Understanding its structure and function can lead to the development of novel therapeutics targeting these disorders.
Study Highlights:
Identification of a stable intermediate form of the 5-HT3A receptor.
Potential new drug target for psychiatric disorders like depression and schizophrenia.
Cryo-electron microscopy and tomography revealed detailed structures of these tetramers in membranes.
Computer simulations provided insights into the assembly pathway of the receptor, suggesting potential functional roles for the tetrameric forms.
We are proud to see our Salipro® technology enabling groundbreaking research and contributing to the discovery of next-generation therapeutics. Congratulations to the research team for this significant achievement!
Read more: B. Introini, W. Cui, X. Chu, et al., Structure of tetrameric forms of the serotonin-gated 5-HT3A receptor ion channel. EMBO J. (2004).